Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients

Inclusion Criteria

• •For Part 1-Healthy Participants
• •18-50 years old (inclusive), male or female
• •Male participants should be ≥ 50 kg, female participants should be ≥ 45 kg; Body Mass Index (BMI) should be between 19 and 30 kg/m2 (inclusive)
• •In good health, with no history of diseases of major organs and no BP, HR, ECG or respiratory abnormality on physical examination
• •Adequate hepatic and renal function, as determined by clinical laboratory assessments of blood and urine
• •Negative serum pregnancy test at Screening and negative urine pregnancy test at Day -1 for females of child bearing potential
• •Negative screen for drugs of abuse, alcohol, hepatitis B surface antigen (HBsAg), hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) at screening; and negative drugs of abuse, alcohol pre dose on Day -1
• •Have signed a written informed consent before entering the study
• •For Part 2 - Patients with Psoriasis
• •Clinical diagnosis of psoriasis for at least six months with multiple affected areas (excluding the face, scalp, genitals and groin) involving 2%-15% of the total Body Surface Area (BSA)
• •18-65 years old
• •Male participants should be ≥ 50 kg, female participants should be ≥ 45 kg; BMI should be between 19 and 35 kg/m2 (inclusive)
• •In good health, with no history of diseases of major organs and no BP, HR, ECG or respiratory abnormality on physical examination
• •Adequate hepatic and renal function, as determined by clinical laboratory assessments of blood and urine
• •Negative serum pregnancy test at Screening and negative urine pregnancy test at Day -1 for females of child bearing potential
• •Negative screen for drugs of abuse, alcohol, HBsAg, HCV and HIV at screening; and negative drugs of abuse, alcohol pre dose on Day1
• •Women of child-bearing potential must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy
• •Have signed a written informed consent before entering the study